Loading
Ensign Group, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 May 2024.
Ensign Group, Inc: what insiders have been doing
Every trade that managers of Ensign Group, Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 76 filings signed by 16 insiders.
All open-market trades in the period are sales: 18 sales worth €1.4M, by 6 insiders, with no purchase on record. One trade stands out by size: a sale of €180k from Shaw Daren, disclosed on 19 February 2026.
With 76 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Since 2016, the database holds 1 purchase and 65 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 5.06 bn USD of revenue and 344.0 m USD of net income and a dividend of 0.25 USD per share.
Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
395
Thresholds
n/a
Buy Volume
€16
1 ops. · all time
Sell Volume
€8M
65 ops. · all time
Who traded when
BuySaleBarry M. Smith17 sales
Ann Scott Blouin6 sales
Daren Shaw6 sales
Agwunobi John O4 sales
Parkinson Mark Vincent3 sales
Pison Marivic Uychiat1 sale
Since the insiders bought
- +12.7%Entry US$116.89 · Close at T+365 US$131.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ensign Group, Inc Buy (bullish), based on 5 analysts. Average price target: US$220.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 14,500 of 24,148 companies
45.5
score / 100
Value44
Quality47
FCF yld3.6%
Earn yld3.3%
EV/EBITDA22.0x
ROE17%
Gross mgn16%
Net mgn6.8%
Debt/EBITDA3.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$176.63
Analyst consensus
5 analystsBuy
US$207.00Target US$220.00(+25%)US$230.00
Income statement
RevenueUS$5.1B
Gross profitUS$799.5M16% margin
EBITDAUS$567.9M11% margin
Net incomeUS$344M6.9% margin
Valuation
PER (trailing)27.7x
PER (forward)20.6x
P/Book4.2x
Beta0.66
Balance sheet & cash
Market capUS$10.3B
Total debtUS$2.2B
Free Cash FlowUS$370.7M
Debt / Equity92%
Profitability & ownership
ROE17.0%
ROA5.5%
% insiders3.5%
% institutions92.1%
Last declaration on 16 October 2026
Declarations395 total
100 shares@ US$179.62CommonSEC144:0001959173-26-007407
580 shares0Common StockSEC:0002085143-26-000006:0
2,500 shares0Common StockSEC:0001778500-26-000010:0
175 shares@ US$181.880.0003% mcap6.0% of flowCommon StockSEC:0001764784-26-000010:0
200 shares@ US$185.000.0004% mcap7.0% of flowCommon StockSEC:0001764784-26-000010:1
375 shares@ US$183.5440.0007% mcap13.0% of flowCommonSEC144:0001959173-26-005370
392 shares@ US$171.060.0007% mcap28.8% of flowCommonSEC144:0001959173-26-005274
600 shares0Common StockSEC:0001764784-26-000008:0
600 shares0Common StockSEC:0001548135-26-000008:0
600 shares0Common StockSEC:0001741453-26-000006:0
600 shares0Common StockSEC:0001627893-26-000010:0
600 shares0Common StockSEC:0001212067-26-000020:0
600 shares0Common StockSEC:0002045482-26-000008:0
100 shares@ US$168.120.0002% mcap30.5% of flowCommonSEC144:0001959173-26-005239
700 shares@ US$164.280.0010% mcap5.6% of flowCommon StockSEC:0001212067-26-000016:0
700 shares@ US$164.280.0011% mcap5.5% of flowCommonSEC144:0001959173-26-004240
281 shares@ US$172.420.0004% mcap0.6% of flowCommon StockSEC:0001778500-26-000008:0
458 shares@ US$172.420.0007% mcap0.8% of flowCommon StockSEC:0001470396-26-000012:0
458 shares@ US$171.970.0007% mcap0.8% of flowCommon StockSEC:0001470396-26-000012:1
264 shares@ US$171.970.0004% mcap0.6% of flowCommon StockSEC:0001778500-26-000008:1
509 shares@ US$172.420.0007% mcap0.9% of flowCommon StockSEC:0001417552-26-000008:0
509 shares@ US$171.970.0007% mcap0.9% of flowCommon StockSEC:0001417552-26-000008:1
123 shares@ US$172.420.0002% mcap1.9% of flowCommon StockSEC:0001475842-26-000008:0
102 shares@ US$171.970.0001% mcap1.6% of flowCommon StockSEC:0001475842-26-000008:1
326 shares@ US$172.420.0005% mcap0.9% of flowCommon StockSEC:0001609878-26-000008:0
25 of 395 declarations
About Ensign Group, Inc
The Ensign Group, Inc. (ticker: ENSG) is a U.S.-listed company trading on the Nasdaq market in the United States. It operates in the post-acute and long-term care space, with a business model centered on the operation, development, acquisition, and ownership of healthcare-related properties and facilities, primarily skilled nursing facilities and senior living communities. The company’s profile is closer to an integrated healthcare operator and specialized real estate investor than to a conventional hospital chain. Founded in 1999, Ensign has expanded over time through disciplined acquisitions, local operating autonomy, and continued reinvestment in complex healthcare assets. ([investor.ensigngroup.net](https://investor.ensigngroup.net/files/doc_financials/2023/q4/2a726b98-24c0-4df7-a4fa-0faa0f9f6a7c.pdf?utm_source=openai))
The company is headquartered in San Juan Capistrano, California, United States. Its footprint spans multiple U.S. states, with a historically meaningful presence in California, Arizona, and other markets across the Sun Belt and the Midwest. Recent company disclosures indicate a presence across 17 states and a portfolio that continued to expand through 2025 and into 2026. ([investor.ensigngroup.net](https://investor.ensigngroup.net/news/news-details/2025/The-Ensign-Group-Reports-Fiscal-Year-and-Fourth-Quarter-2024-Results-Issues-2025-Earnings-Guidance/default.aspx?utm_source=openai))
Read moreShow less
Operationally, Ensign provides a broad range of post-acute healthcare services, including skilled nursing, senior living, physical therapy, occupational therapy, speech therapy, and other rehabilitation-oriented healthcare services. The company also has a meaningful real estate component, acquiring or leasing properties needed to support operations. This hybrid model is strategically important: it gives Ensign access to both operating cash flow and healthcare real estate economics, while also supporting a flexible capital-allocation framework. Compared with more traditional healthcare providers, this structure can be an advantage in fragmented markets where consolidation opportunities remain available. ([investor.ensigngroup.net](https://investor.ensigngroup.net/files/doc_financials/2024/q1/c07fd213-2753-4135-9e7e-935b1d634569.pdf?utm_source=openai))
In competitive terms, Ensign stands out for its decentralized management culture, local operating focus, and recurring ability to integrate new facilities. Full-year 2024 and 2025 results showed continued momentum, and management repeatedly raised annual guidance during the year. In first-quarter 2026, the company again increased its full-year outlook, citing strong operating performance and recent acquisitions. Ensign also raised its quarterly dividend in 2025, underscoring a combination of growth and capital-return discipline. ([investor.ensigngroup.net](https://investor.ensigngroup.net/news/news-details/2025/The-Ensign-Group-Reports-Fiscal-Year-and-Fourth-Quarter-2024-Results-Issues-2025-Earnings-Guidance/default.aspx?utm_source=openai))
For French-speaking investors, ENSG is a specialized U.S. healthcare compounder tied to structural aging trends, the ongoing need for rehabilitation services, and the long-term consolidation of the skilled nursing and senior living industries. The key drivers to monitor remain acquisition-led growth, operating margin execution, occupancy and reimbursement trends, and the company’s ability to keep integrating new sites without diluting returns. Recent acquisitions in multiple states confirm that Ensign remains active and opportunistic in its domestic U.S. market. ([investor.ensigngroup.net](https://investor.ensigngroup.net/news/news-details/2025/The-Ensign-Group-Increases-Operations-in-Arizona/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
